[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-pericarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-pericarditis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,70,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100615100","phase-2-transition-to-kpl-387-monotherapy-dosing--administration-study-100615100",false,"NCT07288216","Transition to KPL-387 Monotherapy Dosing & Administration Study","A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies","Key Inclusion Criteria:\n\n* Has well-controlled recurrent pericarditis (i.e., including having CRP \\\u003C 0.5 mg\u002FdL within 14 days of Baseline and a pericarditis pain NRS score ≤ 3 at Baseline)\n* Has a documented history of CRP elevation (\\> 1 mg\u002FdL) associated with at least one prior acute pericarditis episode, whether the incident event or any pericarditis recurrence\n* Has received treatment for RP for at least 3 months prior to Baseline with standard therapy(ies) and is currently on a stable dosing regimen including NSAIDs and\u002For colchicine, and\u002For glucocorticoids or an IL-1 pathway inhibitor (anakinra or rilonacept).\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies\n* Has had a pericarditis recurrence in the last 3 months prior to Baseline\n* Has received an investigational drug during the 4 weeks before study drug administration or is planning to receive an investigational drug at any time during the study.\n* Has a history of active or untreated, latent tuberculosis (TB) prior to screening.\n* Has a history of immunodeficiency.\n* Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.\n* Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.\n* Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix).\n* Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin\u002Fsoft tissue infection.\n* Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.\n* Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).\n* In the Investigator's opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.","ALL","18 Years","80 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.",[27,28,29],"Recurrent Pericarditis","Heart Diseases","Pericarditis",[31,32,33,27],"Recurrence","Recurrent","KPL-387","RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2026-03-25",{"date":42,"type":21},"2029-12-31",{"name":44,"class":45},"Kiniksa Pharmaceuticals International, plc","INDUSTRY",33,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":69},"100593724","phase-2-phase-23-study-of-kpl-387-in-recurrent-pericarditis-100593724","NCT07010159","Phase 2\u002F3 Study of KPL-387 in Recurrent Pericarditis","A Phase 2\u002F3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis","Key Inclusion Criteria:\n\n* Phase 2 and 3: Has a diagnosis of recurrent pericarditis\n* Phase 2 and 3: Has signs and symptoms of recurrent pericarditis despite treatment with standard therapies\n* Phase 2 and 3: Weighs at least 40 kg\n* Phase 2: Taking NSAIDS and\u002For colchicine (in any combination)\n* Phase 3: Taking NSAIDs and\u002For colchicine and\u002For glucocorticoids (in any combination)\n\nKey Exclusion Criteria:\n\n* Phase 2 and 3: Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies.\n* Phase 2 and 3: Has received an investigational drug during the 4 weeks before screening or is planning to receive an investigational drug at any time during the study.\n* Phase 2 and 3: Has a history of active or untreated, latent tuberculosis (TB) prior to screening.\n* Phase 2 and 3: Has a history of immunodeficiency.\n* Phase 2 and 3: Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.\n* Phase 2 and 3: Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.\n* Phase 2 and 3: Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix).\n* Phase 2 and 3: Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin\u002Fsoft tissue infection.\n* Phase 2 and 3: Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.\n* Phase 2 and 3: Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).\n* Phase 2 and 3: In the Investigator's opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.",{"count":55,"type":21},165,[24,57],"PHASE3","This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.",[29,60,27],"Pericarditis Acute",[31,32,27,33],"2026-06-04",{"date":64,"type":38},"2026-06-08",{"date":66,"type":38},"2025-07-25",{"date":42,"type":21},{"name":44,"class":45},58,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100570519","phase-3-cardiolrx-in-recurrent-pericarditis-maveric-phase-3-100570519","NCT06708299","CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)","CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial","MAVERIC","Inclusion Criteria:\n\n1. Patients 18 years of age or older\n2. A history of recurrent pericarditis with stable disease and currently being treated with an IL-1 blocker, scheduled to be discontinued. Stable disease is defined as:\n\n   * treatment with an IL-1 blocker for at least 12 months,\n   * free of pericarditis recurrence for at least 6 months and this recurrence, if present, must have occurred in the setting of an interruption or tapering of an IL-1 blocker; and\n   * treatment with an unchanged dose and regimen of on an IL-1 blocker for at least 3 months prior to randomization.\n3. Pericarditis pain les or equal than 2 on the 11-point Numerical Rating Scale (NRS) for at least 7 days prior to randomization (Visit 1, Day 1)\n4. C-Reactive Protein (CRP) \\\u003C 1.0 mg\u002FdL during screening within 7 days prior to randomization (Visit 1, Day 1).\n5. Patients who have had a vasectomy or who are willing to use double barrier contraception methods with partners of childbearing potential during the conduct of the trial and for 2 months after the last dose of trial therapy.\n6. Patients of childbearing potential willing to use an acceptable method of contraception starting with trial therapy administration and for a minimum of 2 months after trial completion. Otherwise, these patients must be postmenopausal (at least 1 year absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \\[FSH\\] ≥ 40 mIU\u002FmL \\[or ≥ 40 IU\u002FL\\] if less than 2 years postmenopausal) or be surgically sterile.\n\nAcceptable birth control methods that result in a failure rate of less than 1 % include oral, intravaginal or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); using double-barrier contraception methods with their partners; bilateral tubal occlusion; vasectomised partner; sexual abstinence.\n\nExclusion Criteria:\n\n1. Pericarditis recurrence(s) during IL-1 blocker treatment without interruption or tapering of the IL-1 blocker\n2. Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); systemic autoimmune disease (e.g., systemic lupus erythematosus)\n3. Primary diagnosis of myocarditis (diagnosis of myopericarditis is accepted)\n4. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin during screening within 7 days prior to randomization (Visit 1, Day 1)\n5. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 5 times the upper limit of normal (ULN) or ALT or AST \\> 3x ULN plus bilirubin \\> 2x ULN during screening within 7 days prior to randomization (Visit 1, Day 1).\n6. Sepsis, defined as documented bacteremia during screening within 7 days prior to randomization (Visit 1, Day 1) or other untreated or uncontrolled bacterial infection\\*\n7. Prior history of sustained ventricular arrhythmia(s)\n8. History of diagnosed long QT syndrome\n9. QTc interval \\> 480 msec (biologically female) or \\> 470 msec (biologically male) (please refer to Section 9.2.3 for bundle branch block, bifascicular block and paced rhythm correction) or second or third degree atrioventricular (AV) block in a patient without an implanted functioning pacemaker device during screening within 7 days prior to randomization (Visit 1, Day 1)\n10. Showing suicidal tendency during the last 12 months, as defined by answering \"yes\" to question 4 or 5 of the Columbia Suicide Severity Rating Scale (C-SSRS), administered during screening within 7 days prior to randomization (Visit 1, Day 1)\n11. Participation in a clinical trial in which an investigational drug or device was administered within 30 days of screening or within 5 half-lives of the previous study drug, whichever is longer\n12. Inability or unwillingness to give informed consent\n13. Ongoing drug or alcohol abuse in the opinion of the investigator\n14. On any cannabinoid during the past month or unwilling to stay abstinent from all cannabis products for the duration of the trial\n15. Pregnant or breastfeeding\n16. Current diagnosis of active cancer, with the exception of non-melanoma skin cancer\n17. Any factor, which would make it unlikely that the patient can comply with the trial procedures\n18. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment\n19. Has received systemic immunomodulatory agents as below prior to randomization:\n\n    1. Methotrexate (within 2 weeks)\n    2. Azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, or mercaptopurine (within 24 weeks)\n    3. Canakinumab, TNF inhibitors, IL-6 inhibitors, or janus-activating kinase inhibitors (within 12 weeks)\n    4. Intravenous immune globulin (IVIG) (within 8 weeks)\n    5. Corticosteroids (within 4 weeks)\n20. Known hypersensitivity to the active substance or any of the excipients of the trial",{"count":79,"type":21},110,[57],"Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation.\n\nDouble-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks.\n\nThe objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.",[27],[84,85],"IL-1 blocker-dependent recurrent pericarditis","pharmaceutically cannabidial","2026-06-02",{"date":88,"type":38},"2026-06-03",{"date":90,"type":38},"2025-04-07",{"date":92,"type":21},"2026-10-21",{"name":94,"class":45},"Cardiol Therapeutics Inc.",27,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100580356","phase-2-an-open-label-pilot-study-of-vtx2735-in-recurrent-pericarditis-100580356","NCT06836232","An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis","A Phase 2a, Open-Label Pilot Study to Evaluate the Safety\u002FTolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis","Inclusion Criteria:\n\n* Participants are male or female ≥ 18 years up to ≤ 75 years of age.\n* Capable of giving signed informed consent and able to comply with the protocol\n* Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event\n* Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.\n* CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg\u002FL must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)\n* Pericarditis pain score ≥ 4 based on the 11-point NRS.\n* Stable doses of NSAIDs, colchicine, and\u002For oral corticosteroids (if receiving these treatments)\n\nExclusion Criteria:\n\n* Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.\n* History of clinically significant immunosuppressive disorder, autoimmune\u002Fautoinflammatory disorder, or primary or secondary immunodeficiency.\n* Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.","75 Years",{"count":105,"type":21},50,[24],"This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).\n\nCohort A will include approximately 10 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A\n* A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A\n* An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period\n\nCohort B will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C\n* A 14-day Follow-Up Period\n\nCohort C will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period",[27],[110,111,27,112,113,114,115],"Ventyx","Zomagen","VTX2735","NLRP3 Inhibitor","NLRP3","Inflammasome","2026-05-20",{"date":118,"type":38},"2026-05-22",{"date":120,"type":38},"2025-01-28",{"date":122,"type":21},"2027-10",{"name":124,"class":45},"Zomagen Biosciences Ltd.",18]